Concord Biotech IPO

Concord Biotech IPO will open for subscription from 04 August 2023. the company aims for an issue size of ₹1,551 Cr through this IPO.

Company Overview

Full nameConcord Biotech Limited
IndustryPharmaceuticals and Drugs
Company Website

About Company

Concord Biotech is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology, supplying 200 customers in over 70 countries including regulated markets, such as the United States, Europe and Japan, and India.

As of 31 March 2022, Concord Biotech had six fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, and pimecrolimus. It had a total annual installed fermentation capacity for APIs of 1,250 m3 cubic meters. It has established two DSIR (Department of Science & Industrial Research)-approved R&D units with 163 members. The company operates three manufacturing facilities in Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera.

The Objective of the Issue

  • Achieve the benefits of listing the Equity Shares on the Stock Exchanges and
  • Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

IPO Timetable

IPO Opening date04 August 2023
IPO Closing08 August 2023
Basis of Allotment11 August 2023
Initiation Refund14 August 2023
Credit to Demat Account17 August 2023
Listing Date18 August 2023

IPO details

Issue typeBook Built Issue IPO
IPO issue size₹1,551 Cr – 20,925,652 shares
Fresh IssueNil
Offer for sale₹1,551 Cr – 20,925,652 shares
Face value₹01 per share
Price Band₹705 to ₹741 per share
Lot size20 Shares
Employee Discount₹70 per share
Listing ExchangeBSE & NSE

IPO Lot Size

Retail (Min)120₹14,820
Retail (Max)13260₹192,660
S-HNI (Min)14280₹207,480
S-HNI (Max)671,340₹992,940
B-HNI (Min)681,360₹1,007,760

Reservation Details

QIB Shares Offered50%
NII (HNI) Shares Offered15%
Retail Shares Offered35%

Financial Performance

 FY 2021FY 2022FY 2023
Net income234.89174.93240.08
Margin (%)38.0724.5428.14
(Amount in ₹ Crores)

Valuations & Margins

FY 2021FY 2022FY 2023
PE ratio30.72 – 32.29
RONW (%)26.5516.6420.06
ROCE (%)28.5420.5524.27
EBITDA (%)53.0237.8240.47

Company Promoters

  • Sudhir Vaid
  • Ankur Vaid

Promoter Holding

Pre Issue Share Holding
Post Issue Share Holding

Lead Manager(s)

  • Kotak Mahindra Capital Company Limited
  • Citigroup Global Markets India Private Limited
  • Jefferies India Private Limited

IPO Registrar

C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400083, Maharashtra
Phone: +91 22 49186200

Contact Details

16th floor, B-Wing, Mondeal Heights,
Iscon Cross Road, S.G. Highway, Ahmedabad – 380015
Phone: 079-6813 8700

Allotment Status

Concord Biotech IPO allotment will be available on Link Intime’s website. Click on this link to get allotment status.

Final thoughts

Concord Biotech IPO is going to hit Dalal Street soon. applying for an IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make wise decisions.

Happy Investing

Leave a Comment

Your email address will not be published. Required fields are marked *